Overview

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Status:
Completed
Trial end date:
2018-05-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of BIA 5-1058 200 mg on the pharmacokinetic (PK) of treprostinil
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Treprostinil
Zamicastat